FCGR3A V158F gene polymorphism and trastuzumab response in HER2-positive breast cancer patients

Abstract Breast cancer is considered a multifactorial disease, with genetic factors playing an important role in diagnosis and treatment. FCGR3A encodes the receptor for the Fc portion of immunoglobulin G that has been linked to the trastuzumab response. Our study aimed to investigate the associatio...

Full description

Bibliographic Details
Published in:	Scientific Reports
Main Authors:	Marwa A. Abdel-Wahed, Ghada Sadek Sabbour, Amira I. Hamed, Mohammed Sabry EL Kady, Shaimaa Khalil Mohammed, Menat Allah Ali Mahmoud Shaaban
Format:	Article
Language:	English
Published:	Nature Portfolio 2024-10-01
Subjects:	FCGR3A Gene polymorphism Trastuzumab
Online Access:	https://doi.org/10.1038/s41598-024-76024-6

Similar Items

Single Nucleotide Polymorphism rs10919543 in FCGR2A/FCGR3A Region Confers Susceptibility to Takayasu Arteritis in Chinese Population
by: Fang Qin, et al.
Published: (2016-01-01)

Combined FCGR2A (131H/R) and FCGR3A (158F/V) genotypes and their gender-specific association with chronic and refractory immune thrombocytopenia in Palestinian children
by: Khitam Amer, et al.
Published: (2025-10-01)

FCGR2/3 polymorphisms are associated with susceptibility to Kawasaki disease but do not predict intravenous immunoglobulin resistance and coronary artery aneurysms
by: Paula Uittenbogaard, et al.
Published: (2024-09-01)

Association of FCGR2A rs1801274 and FCGR3A rs396991 polymorphisms with various autoimmune diseases: a meta-analysis
by: Elena Thaler, et al.
Published: (2025-09-01)

FCGR3A F158V alleles frequency differs in multiple myeloma patients from healthy population
by: Michaël Constantinides, et al.
Published: (2024-12-01)

Modeling of clinical phenotypes in systemic lupus erythematosus based on the platelet transcriptome and FCGR2a genotype
by: MacIntosh G. Cornwell, et al.
Published: (2023-04-01)

FCGR2A defines prognostic immune subtypes and drives tumor progression in hepatocellular carcinoma
by: Deyuan Zhong, et al.
Published: (2025-10-01)

Impact of FCGR2A rs1801274 and IL-6R rs2228145 polymorphisms on tocilizumab response in the Iranian population with severe COVID-19
by: Nastaran Injinari, et al.
Published: (2024-10-01)

Anisotropic FCGR behaviour in hot-rolled Mg-3Al-0.5Ce alloy
by: Prakash C. Gautam, et al.
Published: (2024-07-01)

Integrated transcriptomics and proteomics assay identifies the role of FCGR1A in maintaining sperm fertilization capacity during semen cryopreservation in sheep
by: Jiachen Bai, et al.
Published: (2023-08-01)

The Effectiveness of Trastuzumab Combined with Sequential Chemotherapy for Metastatic Gastric Carcinoma with Overexpression of HER2
by: Omar Saavedra Santa Gadea, et al.
Published: (2017-07-01)

Comparative Analysis of <i>FCGR</i> Gene Polymorphism in Pulmonary Sarcoidosis and Tuberculosis
by: Marlena Typiak, et al.
Published: (2023-04-01)

Effects of trastuzumab and trastuzumab emtansine on corrected QT interval and left ventricular ejection fraction in patients with metastatic (HER2+) breast cancer
by: Rea Levicki, et al.
Published: (2023-02-01)

Elk1 enhances inflammatory cell infiltration and exacerbates acute lung injury/acute respiratory distress syndrome by suppressing Fcgr2b transcription
by: Shiyou Wei, et al.
Published: (2024-04-01)

Integrative Pan-Cancer Analysis Confirmed that FCGR3A is a Candidate Biomarker Associated With Tumor Immunity
by: Lilin Li, et al.
Published: (2022-05-01)

Disitamab vedotin in preclinical models of HER2-positive breast and gastric cancers resistant to trastuzumab emtansine and trastuzumab deruxtecan
by: Negar Pourjamal, et al.
Published: (2025-03-01)

Aggressive HER2-Positive Gastric Cancer in a Young Patient, Refractory in Trastuzumab and Progressive with Trastuzumab-Emtansine Treatment
by: Vildana Goga Çmega, et al.
Published: (2024-03-01)

An Engineered Human Fc variant With Exquisite Selectivity for FcγRIIIaV158 Reveals That Ligation of FcγRIIIa Mediates Potent Antibody Dependent Cellular Phagocytosis With GM-CSF-Differentiated Macrophages
by: Tae Hyun Kang, et al.
Published: (2019-03-01)

FCGR2B knockdown alleviates diabetes-induced cognitive dysfunction by altering neuronal excitability
by: Yinmeng Qu, et al.
Published: (2025-06-01)

Fc‐gamma receptor polymorphisms, cetuximab therapy, and overall survival in the CCTG CO.20 trial of metastatic colorectal cancer
by: Daniel Shepshelovich, et al.
Published: (2018-11-01)

FCGR1A Alleviates Ischemic Stroke-induced Injury by Promoting Anti-Inflammatory Microglial Polarization via the AMPK–mTOR Signaling Pathway
by: Meng Liu, et al.
Published: (2025-04-01)

Mechanism of trastuzumab resistance caused by HER-2 mutation in breast carcinomas
by: Kong X, et al.
Published: (2019-07-01)

Machine learning-driven dissection of the obesity-ccRCC interface: FCGR2A emerges as a central coordinator of tumor-immune crosstalk
by: Zhongyuan He, et al.
Published: (2025-10-01)

FCGR2A contributes to M2 macrophages polarization in HCC through IL-4/JAK/STAT6 axis
by: Shaojun Li, et al.
Published: (2025-08-01)

Trastuzumab and cardiotoxicity
by: Petra Sertić, et al.
Published: (2024-01-01)

Quantification of Trastuzumab–HER2 Engagement In Vitro and In Vivo
by: Alena Rudkouskaya, et al.
Published: (2020-12-01)

Systematic Review on the Use of Biosimilars of Trastuzumab in HER2+ Breast Cancer
by: Eleni Triantafyllidi, et al.
Published: (2022-08-01)

Intrathecal trastuzumab versus alternate routes of delivery for HER2-targeted therapies in patients with HER2+ breast cancer leptomeningeal metastases
by: Anna-Maria Lazaratos, et al.
Published: (2023-06-01)

Comprehensive approach for identification of functional FCGR2C alleles resulting in protein expression as a determinant for predicting predisposition to autoimmunity
by: Dorit Lehmann, et al.
Published: (2021-12-01)

Correlation between CTMP expression levels and resistance to trastuzumab in HER2 + metastatic breast cancer
by: Mania Makhoul, et al.
Published: (2025-07-01)

Synthesized Anti-HER2 Trastuzumab-MCC-DM1 Conjugate: An Evaluation of Efficacy and Cytotoxicity
by: Soodabeh Shafiee, et al.
Published: (2023-09-01)

Anti-HER-2 therapy following severe trastuzumab-induced cardiac toxicity
by: Ibrahim Sadek, et al.
Published: (2017-09-01)

Assessment of Carvedilol Therapy in Prevention of Heart Failure in HER2 Positive Breast Cancer Patients Receiving Trastuzumab
by: Alborz Sherafati, et al.
Published: (2019-05-01)

Comparison of T-DM1 and trastuzumab-pertuzumab in HER2-positive breast cancer patients with residual disease after neoadjuvant therapy: a retrospective study
by: Junxiao Wang, et al.
Published: (2025-07-01)

Trastuzumab-based palliative chemotherapy for HER2-positive gastric cancer: a single-center real-world data
by: Tae-Hwan Kim, et al.
Published: (2021-03-01)

Development of cardiac risk prediction model in patients with HER-2 positive breast cancer on trastuzumab therapy
by: Prince Otchere, et al.
Published: (2023-05-01)

Trastuzumab deruxtecan: A quantum leap in HER2-positive breast cancer
by: Manikandan Dhanushkodi
Published: (2019-01-01)

Vasculogenic mimicry is associated with trastuzumab resistance of HER2-positive breast cancer
by: Ami Hori, et al.
Published: (2019-08-01)

Combining Endocrine Therapy with Trastuzumab Emtansine Improves Progression-Free Survival and Overall Survival in HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer
by: Oğuzcan Kınıkoğlu, et al.
Published: (2024-06-01)

Predictors of trastuzumab-induced cardiotoxicity among racially and ethnically diverse patients with HER2-positive breast cancer
by: Anna Vaynrub, et al.
Published: (2024-10-01)